The live blog above is tracking all the action at a U.S. Food and Drug Administration advisory committee meeting, convened to review eteplirsen, Sarepta's experimental drug for the treatment of Duchenne muscular dystrophy.
TheStreet Senior Columnist Adam Feuerstein is providing live coverage and analysis of the Sarepta FDA advisory panel as it happens near Washington, D.C.
At the end of Monday's meeting, a panel of 13 independent experts will vote on a series of questions which will provide recommendation to the FDA on whether or not eteplirsen should be approved, or not.
Sarepta shares are halted for trading while the advisory panel is in session. The stock last traded Friday at $14.95.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.